Clinical Significance of Neutralizing Antibodies in Patients with Chronic Myelogenic Leukemia

[1]  J. Gutterman,et al.  Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa‐2a by intramuscular injection , 1987, Cancer.

[2]  R. Spiegel,et al.  Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). , 1986, The American journal of medicine.

[3]  J. Quesada,et al.  Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Merigan,et al.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. , 1982, Annals of internal medicine.

[5]  K. Cantell,et al.  Immune reactions and long-term therapy with human leukocyte interferon. , 2009, Acta medica Scandinavica.

[6]  Charles Weissmann,et al.  The structure of one of the eight or more distinct chromosomal genes for human interferon-α , 1980, Nature.

[7]  P. Hofschneider,et al.  SUCCESSFUL TREATMENT OF NASOPHARYNGEAL CARCINOMA WITH INTERFERON , 1980, The Lancet.

[8]  J. Greenwood,et al.  Letter: Exploration of the common bileduct. , 1974, Lancet.

[9]  K. Cantell,et al.  Clinical and laboratory investigations on man: systemic administration of potent interferon to man. , 1973, Journal of the National Cancer Institute.

[10]  J. Enders,et al.  AN INHIBITOR OF VIRAL ACTIVITY APPEARING IN INFECTED CELL CULTURES. , 1959, Proceedings of the National Academy of Sciences of the United States of America.